Brain stimulation for increased appetite caused by antipsychotics in schizophrenia
Tests brain stimulation against sham to reduce antipsychotic-driven appetite in schizophrenia.
Plain-language title generated from the registry record
Registry title: iTBS for Increased Appetite Induced by Antipsychotics
Key facts
- Where
- Changsha and Dali, ChinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT05783063, who can take part
Where in China
- Central South UniversityChangsha, ChinaNot yet recruiting
- The Second People's Hospital of Dali Bai Autonomous PrefectureDali, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Central South University
- Trial code
- NCT05783063
- Record updated
- 26 March 2025
- Original description
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.Read full original descriptionShow less
Effects of Intermittent Theta Burst Stimulation (iTBS) on Increased Appetite Induced by Antipsychotics in Patients With Schizophrenia
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
Inclusion: Age between 18-40 years old; Meeting the diagnostic criteria for schizophrenia in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition); BMI ≥ 25kg/m 2 or over 10% weight gain after taking antipsychotics in the last year; Not receiving TMS therapy in the past month; Using no more than two antipsychotic medications (including olanzapine, haloperidol, amisulpride, asenapine, risperidone, paliperidone, clozapine, quetiapine, iloperidone, chlorpromazine, sertindole, zotepine), not using antidepressants, mood stabilizers and other drugs, but allowing short-term use of benzodiazepines, benzhexol and propranolol; Signing written informed consents voluntarily.
Exclusion: Receiving regular MECT, or weight-loss therapy in the latest month; Other severe mental illnesses, mental retardation, dementia and severe cognitive impairment according to diagnostic criteria of ICD-10 or DSM-5; Abnormal brain structure or function owing to any major physical disease, neurological disease, traumatic brain injury, etc; Metallic implants, pacemakers, epilepsy history or other contraindications of TMS; Suicidal thoughts or behaviors; Alcohol or substance abuse; Pregnant or lactating women; Other contraindications of MRI; Other abnormal examination results considered to be inappropriate for inclusion by researchers.